1. Pink Sheet
  2. >>Market Access

Medicare Anti-VEGF Evaluation: TA Notes Safety Comparison Challenges For Avastin, Cost-Benefit Data

 
• By Cathy Kelly

The Institute for Clinical and Economic Review conducted a technology assessment for anti-VEGF agents in diabetic macular edema for CMS in preparation for an upcoming MedCAC review.

Challenges remain in evaluating the safety of Roche’s Avastin (bevacizumab) in diabetic macular edema compared to other anti-VEGF agents, a technology assessment requested by the Centers for Medicare and Medicaid Services concludes.

Released March 12, the TA was conducted by the Institute for Clinical and Economic Review, an academic research and policy...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Market Access

More from Pink Sheet

EUCOPE Wants Simpler Manufacturing Rules And Framework For Combined Trials Under EU Biotech Act

 
• By Eliza Slawther

EU authorities must “take advantage” of the upcoming Biotech Act to reassess the bloc’s policies and “offset existing challenges” for small and midsized enterprises, trade association EUCOPE has said.

Trial Cancellations And Delays Persist For CROs Amid Biotech Slowdown

 
• By Vibha Sharma

The whole contract research organization industry is being impacted by the current volatility in the pharmaceutical industry.

Citeline Japan Awards 2025 - Enter Now!

 
• By Ian Haydock and Lisa Takagi

The 14 July deadline for the Citeline Japan Awards 2025 in Tokyo is approaching fast, so here's a reminder to take a look at the categories and criteria and be sure to get your submissions in by this date. Sponsorship opportunities and tables for the event are also available.